Contact:
Simon Castellanos
877.443.4006
Dallas, Texas – AIS Healthcare is proud to recognize March as Multiple Sclerosis Awareness (MS) month. It is critical to raise awareness and amplify the stories of people living with MS. With nearly 1 million individuals living with MS in the United States, the fight for a cure has never been more important.
Nationally, there is a growing understanding of MS, a chronic disease of the central nervous system, affecting the brain, spinal cord, and optic nerves. “While treatments have been developed to treat the symptoms of MS including pain and spasticity, we must continue working towards a cure for every person living with this disease,” said Simon Castellanos, AIS Healthcare Chief Executive Officer. “AIS Healthcare is committed to providing people living with MS the medication and supports required to live meaningful and joyful lives.”
Though the cause of MS remains unknown, there are effective treatment options for patients that can help manage symptoms and provide support in leading a long and productive life. March is a time to raise awareness, educate society, fundraise, and support the scientific and health care community that is working towards a cure and deepening our understanding of MS.
Advancing quality. Improving lives.
As the leading provider of targeted drug delivery and infusion care solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.
Learn more at aiscaregroup.com
Contact:
Simon Castellanos
877.443.4006
Dallas, Texas -AIS Healthcare is proud to recognize March as Brain Injury Awareness month and celebrates the advances in both care and awareness that have benefitted the brain injury community. AIS Healthcare is committed to improving care in addition to raising awareness for issues that affect the 5.3 million individuals in the United States living with a brain injury or brain injury-related disability.
“Individuals who have acquired a brain injury deserve access to the care and support that enables them to thrive in their careers and lead fulfilling lives,” said Simon Castellanos, AIS Healthcare Chief Executive Officer “At AIS Healthcare, we take pride in our work to offer best-in-class medication and services to support this community.”
The Centers for Disease Control and Prevention (CDC) estimates an average of 1.5 million traumatic brain injuries (TBI) occur each year, however misunderstandings about TBI and its potential impacts are commonplace. This is why Brain Injury Awareness Month is so important for illustrating the need for better understanding and advocacy.
To reduce the occurrence of brain injury, it is recommended to always wear a seatbelt, helmets, and never drive impaired. Reducing the risk of injury lowers the number of people who will need treatment or hospitalization after an injury occurs. For more information about prevention strategies and how to support the brain injury community, contact your local brain injury association by visiting here.
Advancing quality. Improving lives.
As the leading provider of targeted drug delivery and infusion care solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.
Learn more at aiscaregroup.com
CONTACT:
Jud Hall
877.443.4006
Valdosta, GA – Advanced Infusion Care (AIC), a division of AIS Healthcare, announced today the reopening of a newly designed pharmacy in Valdosta, Georgia. The state-of-the-art pharmacy expands the home infusion service provider’s footprint in the southeast and enhances AIC’s ability to service patients across the United States. AIC’s Valdosta pharmacy is its largest pharmacy to-date, with nearly 40 licensed professionals servicing approximately 1,400 patients.
“The Valdosta pharmacy will enhance our industry leading regulatory compliance, quality, and operational flow allowing for sustained growth and expansion into new markets,” said Jud Hall, President at AIC. “This new space will provide optimal working conditions for our team and allow us to continue achieving the highest levels of safety and quality for the patients we serve.”
The pharmacy’s updated layout will benefit operations by expanding production areas and ultimately boosting staff efficiency. Patients using AIC’s services benefit from 24/7 access to dedicated clinical and support staff including clinical pharmacists, infusion nurse specialists, and intake managers. AIC’s Valdosta location was originally purchased by the company in 2017.
AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC), further setting it apart from other infusion services providers.
Physicians interested in AIC care services should contact their AIC representatives to get started or visit us at www.aiscaregroup.com/our-divisions/infusion-care/
Advancing quality. Improving lives.
As the leading provider of targeted drug delivery and infusion care solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.
Learn more at aiscaregroup.com
CONTACT:
Jud Hall
877.443.4006
Dallas, TX- Advanced Infusion Care, a division of AIS Healthcare, now offers GAMMAKED™, developed by Kedrion for the treatment of patients with primary humoral immunodeficiency (PI), idiopathic thrombocytopenic purpura (ITP) in adults and children, and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
The nationally accredited home infusion teams at AIC collaborate closely with physicians to provide specialized in-home infusion services. This new therapy option, offered under a limited distribution contract with Kedrion, expands AIC’s ability to serve immunoglobulin (Ig) infusion patients.
“We’re proud to be able to add GAMMAKED™ to our growing list of Ig infusion therapies,” said Jud Hall, President at AIC. “This therapy from Kedrion can help us provide additional treatment options for our patients.”
GAMMAKED™ is indicated for the treatment of PI in patients 2 years of age or older, ITP in adults and children, and CIDP in adults. Approved by the U.S Food and Drug Administration in 2011, the therapy is now available at all AIC locations (Valdosta, Georgia; Birmingham, Alabama; Clinton, Mississippi; Panama City, Florida; Dallas, Texas).
Like all AIC patients, those with PI, ITP, and CIDP will receive a high level of care from AIC, including 24/7 access to clinical and support staff. Every patient is assigned a dedicated team of professionals, including clinical pharmacists, infusion nurse specialists, and intake managers to provide support throughout the treatment process.
For physicians, AIC is a full-service care delivery partner. We have contracts with multiple immunoglobulin suppliers, like Kedrion. These contracts help us ensure prescribed therapies are always in stock. We also work directly with patients, insurance companies, and physician offices to secure all needed authorizations and complete paperwork.
AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC), further setting it apart from other infusion services providers.
Physicians interested in AIC care services should contact their AIC representatives to get started or visit us at www.aiscaregroup.com/our-divisions/infusion-care/
Advancing quality. Improving lives.
As the leading provider of targeted drug delivery and infusion care solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.
Learn more at aiscaregroup.com.
Kedrion Biopharma is a global biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating and preventing serious diseases, disorders and conditions. It’s portfolio of 37 life-saving products are distributed in over 100 countries.
In 2022, Kedrion joined forces with UK based BPL (Bio Products Laboratory) forming the 5th top player in plasma derivatives and rare disease medicines, employing more than 4,800 people worldwide.
Kedrion places a high value on the welfare of those who benefit from its products, as well as the communities and individuals with whom it works and collaborates. It acts as a bridge between donors and the people who need treatment, working on a global scale to expand patient access to plasma-derived therapies.
AIS Healthcare (AIS), through its counsel King & Spalding, secured a settlement and new network contract following a lawsuit with Blue Cross Blue Shield of Mississippi (Blue Cross) over home infusion therapy per diem billing. AIS is a leader in the healthcare industry for these services.
AIS sued Blue Cross for breach of contract for non-payment. Blue Cross counterclaimed, alleging that AIS had misrepresented its bills by including per diem charges for each day the therapy is administered via an implanted pain pump – i.e., billing code S9328. AIS showed during the course of the lawsuit that the way it bills is appropriate and industry standard for these services.
After a full investigation and evaluation of AIS billing per diems, Blue Cross, as well as the Blue Cross Blue Shield Association, both acknowledged, in a written settlement statement, there was in fact no fraud by AIS, and no finding of waste or abuse by AIS.
In agreeing to end their litigation, Blue Cross and the Association also confirmed, in the written settlement statement, that the parties have reached an agreement for Blue Cross to pay for past AIS services, and an agreement for AIS to be in-network again for the Federal Employee Benefits Program (FEP).
AIS was represented by King & Spalding healthcare and litigation partner Glenn Solomon along with trial partner Peter Strotz, who is also managing partner of the firm’s Los Angeles office, and experienced healthcare counsel Jonathan Shin. Overseeing the King & Spalding legal team that handled the lawsuit and negotiations was AIS Chief Legal Officer John Finley.
See link to a full copy of the Written Settlement Statement. The lawsuit was venued in federal court in the U.S. District Court for the Southern District of Mississippi. The court entered dismissal of the lawsuit earlier this November.
The designation continues to reflect AIS Healthcare’s commitment to advancing quality at its compounding pharmacies in Mississippi and Texas as well as Advanced Infusion Care locations in Georgia, Alabama, Mississippi, Florida, and Texas.
Dallas, Texas—AIS Healthcare is proud to announce that its two state-of-the-art 503A compounding pharmacies (Ridgeland, Mississippi; Dallas, Texas) which produces patient-specific prescriptions for targeted drug delivery (TDD), and it’s five Advanced Infusion Care locations (Valdosta, Georgia; Birmingham, Alabama; Clinton, Mississippi; Panama City, Florida; Dallas, Texas) have received the prestigious URAC accreditation for Specialty Pharmacy.
URAC is the independent leader in promoting healthcare quality through leadership, accreditation, measurement and innovation. By achieving re-accredited status, AIS Healthcare has demonstrated its commitment to going above and beyond to improve quality at every point along the care continuum.
“These accreditations are validation of what we do day in and day out—advancing quality,” said Michelle Wiest, Chief Operations Officer, AIS Healthcare. “It’s a prestigious recognition, and we’re proud to receive it for six of our leading pharmacies.”
AIS Healthcare is the leading targeted drug delivery and infusion care provider. In addition to compounding patient-specific prescriptions at its state-of-the-art 503A specialty pharmacies and providing personalized in-home infusion services, AIS Healthcare also offers a comprehensive suite of services to support both patients and providers.
“Throughout AIS Healthcare, we’re focused on doing more of what matters throughout the care continuum,” said Cindy Dumas, Vice President of Pharmacy Services and Pharmacist-in-Charge, Ridgeland. “This recognition from URAC shows how doing more to advance quality truly does result in meaningful improvements for patients and providers.”
AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC), further setting it apart from other compounding pharmacies and infusion services providers.
The URAC accreditations for Specialty Pharmacy are effective through November 1, 2025.
Advancing quality. Improving lives.
As the leading provider of targeted drug delivery and infusion care solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.
Learn more at aiscaregroup.com
Founded in 1990, URAC is the independent leader in promoting healthcare quality through leadership, accreditation, measurement and innovation. URAC is a nonprofit organization using evidence-based measures and developing standards through inclusive engagement with a range of stakeholders committed to improving the quality of healthcare. Our portfolio of accreditation and certification programs span the healthcare industry, addressing healthcare management, healthcare operations, health plans, pharmacies, telehealth providers, physician practices and more. URAC accreditation is a symbol of excellence for organizations to showcase their validated commitment to quality and accountability.
AIS HealthCare™ is pleased to welcome Anish S. Patel, MD, MBA as Chief Medical Officer (CMO) where he will continue to advance our clinical and quality agenda to improve patient outcomes and therapy development.
As Chief Medical Officer, Dr. Patel will oversee and take an active role in the overall Quality of Pharmacy operations as well as enhancing the continuum of patient care through our Advanced Care Coordination Solutions (ACCS) and Advanced Nursing Solutions (ANS) offerings. In addition, Dr. Patel will help coordinate and expand our research and studies program, data analytics, therapy education and serve as a liaison between our Hospital Accounts, Neuromodulation and Pain Societies and Government Relations. In addition, he will lead the AIS Medical Advisory Board.
Dr. Patel is double-board certified in anesthesiology and pain medicine and currently serves as Vice-President and Managing Partner at National Spine and Pain Centers. He attended MGR Medical University, an affiliate of Harvard Medical International in India. Following medical school, he returned to Detroit where he completed a residency in Anesthesiology serving as chief resident in his final year before pursuing fellowship training in Interventional Pain Management at Brigham and Women’s Hospital, Harvard Medical School.
Dr. Patel is known for a truly multidisciplinary approach to pain management, utilizing interventional, medical and rehabilitative techniques. He strives to provide his patients with compassionate care to improve their lifestyle and sense of well-being.
Among his achievements, he has served as a member of the following professional organizations:
“I am very excited to join AIS HealthCare™ to continue to raise the bar on their already best-in-class quality and process standards to ultimately deliver infusion solutions for improved health outcomes and a better level of care,” stated Dr. Anish Patel, new Chief Medical Officer of AIS HealthCare™. “I look forward to continuing the Patient Safety. First!™ philosophy they have instilled in their employees.”
To learn more about AIS HealthCare™ and how the company is delivering on its unwavering commitment to patient safety, please visit www.aiscaregroup.com.
Dr. Patel may be reached at: apatel@aiscaregroup.com
As the designated 503A provider with Premier, AIS Healthcare will offer its TDD pump medications to Premier’s alliance of 4,000 U.S. hospitals and 165,000 other providers.
The recently released 20% subcutaneous immunoglobulin therapy expands treatment options offered by Advanced Infusion Care.
Valdosta, GA—Advanced Infusion Care, a division of AIS Healthcare, now offers Xembify®, developed by Grifols for the treatment of primary immune deficiency disease (PIDD).
AIC’s nationally accredited home infusion teams collaborate closely with physicians to provide specialized in-home infusion services. This new therapy option, offered under a limited distribution partnership with Grifols, expands AIC’s ability to serve
immunoglobulin (Ig) infusion patients.
“We’re proud to be able to add Xembify® to our growing list of Ig infusion therapies,” said Jud Hall, Senior Vice President at AIS Healthcare. “This new therapy from Grifols can help us provide additional treatment options for our PIDD patients.”
Xembify® is for the treatment of PIDD in patients 2 years of age and older. Approved by the U.S. Food and Drug Administration on July 3, 2019, the therapy was launched in the United States on November 18 and is now available at all AIC locations.
Like all AIC patients, PIDD patients receive a high level of care from AIC, including 24/7 access to clinical and support staff. Every patient is assigned a dedicated team of professionals, including clinical pharmacists, infusion nurse specialists, patient care
managers and intake managers, to provide support throughout the treatment process.
For physicians, AIC is a full-service care delivery partner. We have contracts with multiple immunoglobulin suppliers like Grifols to help ensure prescribed therapies are always in stock. We also work directly with patients, insurance companies and physician offices to secure all needed authorizations and complete paperwork.
AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC).
Physicians interested in AIC care services should contact their AIC representatives to get started or visit us at aiscaregroup.com/advanced-infusioncare-overview.php.
Advancing quality. Improving lives.
As the nation’s top intrathecal and infusion care solutions provider, AIS Healthcare is committed to doing more of what matters for patients and providers. From the industry leading quality and sterility standards at our pharmacies to our comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do. Because when we do more to advance care quality, providers are empowered and patients are supported. Days get easier. Lives get better.
Learn more at aiscaregroup.com
Grifols is a global healthcare company with more than 75 years of history improving the health and well-being of people around the world. Grifols produces essential plasma medicines for patients and provides hospitals, pharmacies and healthcare professionals with the tools, information and services they need to efficiently deliver expert medical care. Grifols’ three divisions—Bioscience, Diagnostic and Hospital—develop, produce and market innovative products and services available in more than 100 countries.
Learn more at grifols.com
AIS Healthcare is proud to announce that its two state-of-the-art 503A compounding pharmacies and its four Advanced Infusion Care locations have received the prestigious URAC accreditation in Specialty Pharmacy, and its Dallas-based Care Coordination Program has been awarded URAC accreditation for Health Call Center.